Therefore, in this paper we investigate whether a computationally derived short antisense peptide, targeting a selected epitope of the human prostate specific antigen (hPSA) could be used in preference to the standard monoclonal antibody for staining the PSA biomarker in human prostate cancer tissue [10,11,12,13,14,15,16,17,18,19,20,21,22]. This evidence concerns the gene KLK3 and prostate carcinoma.